ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer [0.03%]
ACE-Breast-02：ARX788与拉帕替尼联合卡培他滨治疗HER2阳性晚期乳腺癌的随机III期试验
Xichun Hu,Qingyuan Zhang,Leiping Wang et al.
Xichun Hu et al.
This phase III trial aimed to compare ARX788, a site-specific, construct-homogeneous antibody-drug conjugate, with lapatinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer ...
Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine [0.03%]
拉帕替尼联合卡培他滨治疗后进展的HER2阳性乳腺癌患者的曲妥珠单抗再挑战疗法
Nijat Khanmammadov,Izzet Doğan,Bayarmaa Khishigsuren et al.
Nijat Khanmammadov et al.
Data regarding the use of rechallenge trastuzumab (RTmab)-based therapies in the management of heavily pretreated patients with HER2-positive breast cancer (BC) in the literature are limited. This study aimed to evaluate the efficacy of tra...
Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients [0.03%]
拉帕提尼联合卡培他滨治疗T-DM1治疗后HER2阳性转移性乳腺癌患者的有效性研究
Izzet Dogan,Anıl Yıldız,Melin Aydan Ahmed et al.
Izzet Dogan et al.
Different targeted therapy options exist for treating HER2-positive metastatic breast cancer patients. This study evaluated the efficacy and tolerability of the lapatinib plus capecitabine combination after TDM-1 in HER2-positive metastatic...
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy [0.03%]
ELAINA主要研究结果：对于接受过曲妥珠单抗治疗的中国HER2阳性局部晚期或转移性乳腺癌患者的疗效和安全性泰瑟利 vs 拉帕替尼联合卡培他滨 III期、多中心、开放标签试验
Xiaojia Wang,Wei Li,Yongmei Yin et al.
Xiaojia Wang et al.
Background: The antibody-drug conjugate (ADCs) trastuzumab emtansine (T-DM1) is approved for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab and ...
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study [0.03%]
一项关于HER2阳性转移性乳腺癌脑转移患者使用T-DM1和拉帕替尼联合卡培他滨治疗的现实世界研究
Thibaut Sanglier,Jinjoo Shim,Neil Lamarre et al.
Thibaut Sanglier et al.
Background: Trastuzumab emtansine (T-DM1) has demonstrated improvements in survival and neurological symptoms in patients with breast cancer with brain metastases (BCBM). This real-world study investigated the effectivene...
Observational Study
Breast (Edinburgh, Scotland). 2023 Jun:69:441-450. DOI:10.1016/j.breast.2023.01.007 2023
Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis [0.03%]
对于中国HER2阳性的转移性乳腺癌，作为三线疗法的来那替尼联合卡培他滨与拉帕替尼联合卡培他滨的成本效益分析
Yue Wu,Zhu Dong,Jiangfeng Wang et al.
Yue Wu et al.
Objective: Neratinib plus capecitabine (Ner+Cap) were proved to be clinically beneficial as a third-line treatment for women with human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC). Th...
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage [0.03%]
吡咯替尼联合卡培他滨对比拉帕提尼联合卡培他滨治疗中国HER2阳性转移性乳腺癌的成本效果分析：医疗保障覆盖情景分析
Yuwen Bao,Zhuolin Zhang,Xuan He et al.
Yuwen Bao et al.
Background: The overexpression of the human epidermal growth factor receptor-2 (HER2) gene is present in 20~25% of breast cancer (BC) patients, contributing to an inferior prognosis. Recent clinical trials showed that pyr...
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study [0.03%]
吡咯替尼联合 vinorelbine 与 lapatinib 联合卡培他滨治疗经一线及以上抗HER2治疗的晚期乳腺癌患者的疗效：多中心回顾性研究
Yizhao Xie,Yi Li,Luo Ting et al.
Yizhao Xie et al.
Background: Pyrotinib is a newly-developed irreversible pan-ErbB (erythroblastic leukemia viral oncogene homolog) receptor oral tyrosine kinase inhibitor (TKI) with promising efficacy in the human epidermal growth factor ...
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer [0.03%]
NALA III期neratinib联合卡培他滨对比拉帕替尼联合卡培他滨治疗经治的转移性乳腺癌患者的生物标志物分析
Cristina Saura,Judit Matito,Mafalda Oliveira et al.
Cristina Saura et al.
Purpose: Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 pati...
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial [0.03%]
吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2阳性转移性乳腺癌的疗效：PHOEBE三期随机对照临床试验
Binghe Xu,Min Yan,Fei Ma et al.
Binghe Xu et al.
Background: Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversi...
Clinical Trial
The Lancet. Oncology. 2021 Mar;22(3):351-360. DOI:10.1016/S1470-2045(20)30702-6 2021
耗时 0.12206 秒，为您在
48285708
条记录里面共找到 60 篇文章 [XML]